These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 15373047

  • 1. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
    MMW Fortschr Med; 2004 Apr 26; 146 Spec No 1():44. PubMed ID: 15373047
    [No Abstract] [Full Text] [Related]

  • 2. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004 Apr 26; 16(3):9-10. PubMed ID: 17219610
    [No Abstract] [Full Text] [Related]

  • 3. Boosted Reyataz: 48-week results.
    Huff B.
    GMHC Treat Issues; 2004 Apr 26; 18(1-2):15. PubMed ID: 15119279
    [No Abstract] [Full Text] [Related]

  • 4. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
    MMW Fortschr Med; 2004 Apr 26; 146 Spec No 1():90. PubMed ID: 15373065
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A new protease inhibitor from Bristol-Myers Squibb.
    TreatmentUpdate; 2001 Apr 26; 12(12):5. PubMed ID: 11570092
    [No Abstract] [Full Text] [Related]

  • 7. Anti-HIV agents. Promising results from a saquinavir study.
    TreatmentUpdate; 2007 Jan 26; 19(1):9-10. PubMed ID: 17390482
    [No Abstract] [Full Text] [Related]

  • 8. Combined protease results continue to hold up.
    McGuire S.
    Posit Aware; 1997 Jan 26; 8(1):15. PubMed ID: 11364089
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 26; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 10. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003 Jul 26; 15(4):1-2. PubMed ID: 17216850
    [No Abstract] [Full Text] [Related]

  • 11. [New protease inhibitor against HIV. Viral load decreases--without lipid increase].
    MMW Fortschr Med; 2003 Aug 21; 145(33-34):61. PubMed ID: 14526586
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
    MMW Fortschr Med; 2014 Jun 12; 156 Suppl 1():52. PubMed ID: 25026859
    [No Abstract] [Full Text] [Related]

  • 14. Saquinavir/low-dose ritonavir: its use in HIV infection.
    Johnson M, Peters B.
    AIDS Rev; 2003 Jun 12; 5(1):44-51. PubMed ID: 12875107
    [Abstract] [Full Text] [Related]

  • 15. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B.
    GMHC Treat Issues; 2003 Jun 12; 17(6):8-11. PubMed ID: 12913962
    [No Abstract] [Full Text] [Related]

  • 16. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.
    Losso MH, Lourtau LD, Toibaro JJ, Saenz C, González C.
    Antivir Ther; 2004 Dec 12; 9(6):1031-3. PubMed ID: 15651762
    [No Abstract] [Full Text] [Related]

  • 17. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun 12; 18(101):104. PubMed ID: 19637415
    [Abstract] [Full Text] [Related]

  • 18. Data in from first head-to-head protease inhibitor.
    AIDS Patient Care STDS; 1998 Apr 12; 12(4):317. PubMed ID: 11361961
    [No Abstract] [Full Text] [Related]

  • 19. Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.
    Portilla J, Boix V, Garcia-Henarejos JA, Llopis C, Martínez-Madrid O, Gimeno A, Sánchez-Paya J, Merino E.
    Int J STD AIDS; 2005 Dec 12; 16(12):807-10. PubMed ID: 16336763
    [Abstract] [Full Text] [Related]

  • 20. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 12; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.